Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Argenica Therapeutics Ltd AGN


Primary Symbol: AGNTF

Healthcare
Argenica Therapeutics Limited is an Australia-based biotechnology company, developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. The Company's lead neuroprotective peptide candidate, ARG-007, has been demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischemic encephalopathy (HIE). The Company has initiated a Phase 2 clinical trial in acute ischemic stroke patients, as well as continuing to generate preclinical data in other neurological conditions.


OTCPK:AGNTF - Post by User

Argenica Therapeutics Ltd
<< Previous
 Bullboard Posts
User Avatar Image
(0)
•••
Post by LiverTherapyon Feb 07, 2019 3:40pm
159 Views
Post# 29334288

AGN Phase 3 NASH clinical trial update

AGN Phase 3 NASH clinical trial updatehttps://seekingalpha.com/article/4239121-allergan-cenicriviroc-phase-3-nash-fibrosis-correcting-misinterpretation
<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities